The high level of efficacy observed with the combination of bortezomib, lenalidomide, and dexamethasone in the phase III SWOG S0777 study significantly changed the frontline treatment paradigm for patients with multiple myeloma.
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering, discusses what is on the horizon for the use of PD-L1 agents in liver cancer.
Precision oncology should play a vital role in the shift toward value-based medicine by helping to deliver more effective therapies with more manageable pricing profiles.
A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma, including a host of targeted therapies and various immune checkpoint inhibitors.
Navesh K. Sharma, DO, PhD, discusses the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in patients with liver metastatic colorectal cancer.
By working together, the potential for clinical benefit in patients with cancer is increasingly bright.